Eli Lilly stock has ripped higher this year-and its earnings report could pump it up even more, Jacob Sonenshine writes in this week’s edition of Barron’s. Lilly’s obesity drugs are front and center this quarter. And if sales of those drugs do drive a solid earnings report, the stock should gain despite worries about valuation, the author says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- LLY Earnings this Week: How Will it Perform?
- Eli Lilly reports ‘positive’ topline results from LIBRETTO-431 study
- NULG: Check Out This Large-Cap Growth ETF’s Strong Performance
- Eli Lilly price target raised to $510 from $475 at JPMorgan
- Next major rally in biotech likely not until end of 2024, says Capital One